{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:17:00Z","timestamp":1785597420310,"version":"3.56.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ekir.2026.106547","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:08:55Z","timestamp":1776384535000},"page":"106547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus"],"prefix":"10.1016","volume":"11","author":[{"given":"Luxcia","family":"Kugathasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel H.A.","family":"Muskiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Won","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106547_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2213-8587(13)70112-8","article-title":"Diabetes: a 21st century challenge","volume":"2","author":"Zimmet","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2026.106547_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2026.106547_bib4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.clinthera.2021.07.015","article-title":"Prevalence of chronic kidney disease in type 2 diabetes: the Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study","volume":"43","author":"Chu","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.ekir.2026.106547_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100532","article-title":"CKD progression and economic burden in individuals with CKD associated with type 2 diabetes","volume":"4","author":"Mullins","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2026.106547_bib6","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2337\/dc21-0220","article-title":"Projecting the incidence of type 2 diabetes\u2013related end-stage kidney disease until 2040: a comparison between the effects of diabetes prevention and the effects of diabetes treatment","volume":"44","author":"Morton","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib7","series-title":"Diabetes in Canada: Facts and Figures From a Public Health Perspective: Public Health Agency of Canada","year":"2011"},{"issue":"20 Suppl","key":"10.1016\/j.ekir.2026.106547_bib8","first-page":"S369","article-title":"Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes","volume":"27","author":"Betts","year":"2021","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ekir.2026.106547_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/dom.14698","article-title":"Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries","volume":"24","author":"Norhammar","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106547_bib10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1159\/000489913","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis","volume":"43","author":"Wang","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2026.106547_bib11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib13","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2901","article-title":"The effect of statins on renal outcomes in patients with diabetic kidney disease: a systematic review and meta-analysis","volume":"33","author":"Qin","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ekir.2026.106547_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.therap.2021.10.002","article-title":"Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysis of randomised control-trials","volume":"77","author":"Sun","year":"2022","journal-title":"Therapies"},{"key":"10.1016\/j.ekir.2026.106547_bib16","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106547_bib17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.kint.2016.11.023","article-title":"Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits","volume":"91","author":"Oellgaard","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106547_bib18","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106547_bib19","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2026.106547_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib26","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib27","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.106547_bib29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12882-022-02763-1","article-title":"The effect of renin\u2013angiotensin\u2013aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials","volume":"23","author":"Alsalemi","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106547_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911203","article-title":"Changes in proximal tubular reabsorption modulate microvascular regulation via the TGF system","volume":"23","author":"Poursharif","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.106547_bib34","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc22-2003","article-title":"Glomerular hyperfiltration predicts kidney function decline and mortality in type 1 and type 2 diabetes: a 21-year longitudinal study","volume":"46","author":"Moriconi","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106547_bib36","doi-asserted-by":"crossref","first-page":"R410","DOI":"10.1152\/ajpregu.00083.2024","article-title":"Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4\/MyD88\/NF-\u03baB pathway in diabetic kidney disease","volume":"327","author":"Huang","year":"2024","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ekir.2026.106547_bib37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/jcm4061325","article-title":"Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade","volume":"4","author":"Perez-Gomez","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2026.106547_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41581-023-00782-1","article-title":"New and emerging therapies for diabetic kidney disease","volume":"20","author":"Correa-Rotter","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib39","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7\u201336: a physiological incretin in man","volume":"330","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/361362a0","article-title":"Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7\u201337)","volume":"361","author":"Holz","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2026.106547_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib42","series-title":"Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)","author":"Latif","year":"2021"},{"key":"10.1016\/j.ekir.2026.106547_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ekir.2026.106547_bib44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Research Support, Non-U.S. gov\u2019t. review","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2026.106547_bib45","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/ph18050668","article-title":"The Efficacy and Safety of Tirzepatide in Patients with Diabetes and\/or Obesity: systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"18","author":"Liu","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ekir.2026.106547_bib46","article-title":"Triple-hormone combination retatrutide induces 24% body weight loss","volume":"330","author":"Harris","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106547_bib47","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b7 4 mg with once-weekly semaglutide 2\u00b7 4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dom.12601","article-title":"Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men","volume":"18","author":"Muskiet","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106547_bib49","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Research Support, Non-U.S. Gov\u2019t","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib50","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2026.106547_bib51","first-page":"1","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"CardioVasc Diabetol"},{"key":"10.1016\/j.ekir.2026.106547_bib52","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/dom.14776","article-title":"Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"24","author":"Yuan","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106547_bib53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2026.106547_bib54","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/dc23-0231","article-title":"Dulaglutide and kidney function\u2013related outcomes in type 2 diabetes: a REWIND post hoc analysis","volume":"46","author":"Botros","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib55","doi-asserted-by":"crossref","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Dulaglutide in diabetes and chronic kidney disease: AWARD-7 exploratory analysis of clinical outcomes","volume":"2","author":"Tuttle","year":"2020","journal-title":"Kidney"},{"key":"10.1016\/j.ekir.2026.106547_bib56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib57","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib58","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2337\/dc24-1773","article-title":"Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1\u20135 clinical trials","volume":"48","author":"Apperloo","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib59","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib60","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.ekir.2025.03.049","article-title":"The Effect of Retatrutide on Kidney Parameters in Participants with type 2 diabetes mellitus and\/or Obesity","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106547_bib61","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/S0140-6736(25)01776-3","article-title":"Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?","volume":"406","author":"Muskiet","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ekir.2026.106547_bib64","doi-asserted-by":"crossref","first-page":"F815","DOI":"10.1152\/ajprenal.00304.2024","article-title":"Endothelin-1 signaling in the kidney: recent advances and remaining gaps","volume":"328","author":"Brooks","year":"2025","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ekir.2026.106547_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","article-title":"Endothelin receptor antagonists in chronic kidney disease","volume":"21","author":"Smeijer","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib66","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/j.2040-4603.2011.tb00344.x","article-title":"Physiology of endothelin and the kidney","volume":"1","author":"Kohan","year":"2011","journal-title":"Compr Physiol"},{"key":"10.1016\/j.ekir.2026.106547_bib67","doi-asserted-by":"crossref","first-page":"R388","DOI":"10.1152\/ajpregu.00478.2015","article-title":"Therapeutic potential of endothelin receptor antagonism in kidney disease","volume":"310","author":"Czopek","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ekir.2026.106547_bib68","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/01.HYP.35.3.732","article-title":"Mechanisms of big endothelin-1\u2013induced diuresis and natriuresis: role of ET(B) receptors","volume":"35","author":"Hoffman","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2026.106547_bib69","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1146\/annurev.pharmtox.47.120505.105134","article-title":"Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease","volume":"47","author":"Schneider","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ekir.2026.106547_bib70","doi-asserted-by":"crossref","first-page":"F1205","DOI":"10.1152\/ajprenal.00578.2007","article-title":"Renal medullary ETB receptors produce diuresis and natriuresis via NOS1","volume":"294","author":"Nakano","year":"2008","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ekir.2026.106547_bib71","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/nep.14130","article-title":"Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?","volume":"28","author":"Chung","year":"2023","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2026.106547_bib72","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.2005121256","article-title":"The endothelin system and its antagonism in chronic kidney disease","volume":"17","author":"Dhaun","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib73","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106547_bib74","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib75","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib76","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib77","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib78","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1111\/bph.15698","article-title":"Soluble GC stimulators and activators: past, present and future","volume":"181","author":"Sandner","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ekir.2026.106547_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177175","article-title":"Soluble guanylyl cyclase stimulators and activators: promising drugs for the treatment of hypertension?","volume":"987","author":"Gawrys","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ekir.2026.106547_bib80","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41581-021-00429-z","article-title":"Nitric oxide signalling in kidney regulation and cardiometabolic health","volume":"17","author":"Carlstr\u00f6m","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib81","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-019-1584-6","article-title":"Structural insights into the mechanism of human soluble guanylate cyclase","volume":"574","author":"Kang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2026.106547_bib82","doi-asserted-by":"crossref","first-page":"H135","DOI":"10.1152\/ajpheart.00908.2024","article-title":"Endothelial dysfunction in chronic kidney disease: a clinical perspective","volume":"329","author":"Cho","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ekir.2026.106547_bib83","doi-asserted-by":"crossref","first-page":"F671","DOI":"10.1152\/ajprenal.00042.2016","article-title":"The role of cGMP and its signaling pathways in kidney disease","volume":"311","author":"Shen","year":"2016","journal-title":"Am J Physiol Ren Physiol"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.106547_bib84","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.ekir.2026.106547_bib85","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ncpneph0143","article-title":"Arginine, arginine analogs and nitric oxide production in chronic kidney disease","volume":"2","author":"Baylis","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib86","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3390\/jcm9082359","article-title":"Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update","volume":"9","author":"Roumeliotis","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2026.106547_bib87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2215\/CJN.08410520","article-title":"Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial","volume":"16","author":"Hanrahan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib88","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","article-title":"Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib89","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ndt\/gfae261","article-title":"The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"40","author":"Gansevoort","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106547_bib90","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.15420\/cfr.2025.09","article-title":"The emerging role of aldosterone synthase inhibitors in overcoming renin\u2013angiotensin\u2013aldosterone system therapy limitations: a narrative review","volume":"11","author":"Patel","year":"2025","journal-title":"J Card Fail [Review]"},{"key":"10.1016\/j.ekir.2026.106547_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1423027","article-title":"Evaluating the role of aldosterone synthesis on adrenal cell fate","volume":"15","author":"Aminuddin","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ekir.2026.106547_bib93","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/dom.15518","article-title":"Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: a multicentre, randomized, double-blind, placebo-controlled, Phase I trial","volume":"26","author":"Bornstein","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106547_bib94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib95","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib96","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib97","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cytogfr.2025.05.007","article-title":"Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression","volume":"84","author":"Ansari","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ekir.2026.106547_bib98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000550094","article-title":"The role of inflammation and high-sensitivity C-reactive protein in atherosclerotic cardiovascular disease and chronic kidney disease: the FLAME-ASCVD survey among nephrologists","volume":"16","author":"Perkovic","year":"2025","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.ekir.2026.106547_bib99","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106547_bib100","series-title":"From RESCUE to ZEUS: Will Interleukin-6 Inhibition With Ziltivekimab Prove Effective for Cardiovascular Event Reduction?","author":"Ridker","year":"2021"},{"key":"10.1016\/j.ekir.2026.106547_bib101","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1016\/j.ekir.2024.11.1354","article-title":"WCN25-888 design of the ZEUS trial: interleukin 6 inhibition with ziltivekimab for cardiovascular protection in chronic kidney disease","volume":"10","author":"Perkovic","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106547_bib102","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000537942","article-title":"Rilparencel (renal autologous cell therapy-REACT\u00ae) for chronic kidney disease and type 1 and type 2 diabetes: phase 2 trial design evaluating bilateral kidney dosing and redosing triggers","volume":"55","author":"Stavas","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib103","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000527582","article-title":"Renal autologous cell therapy in type 2 diabetes with late stage 4 diabetes-related chronic kidney disease: trial design and early analysis","volume":"52","author":"Stavas","year":"2023","journal-title":"Blood Purif"},{"issue":"10","key":"10.1016\/j.ekir.2026.106547_bib104","first-page":"1681","article-title":"Renal autologous cell therapy in diabetes and CKD: TH-PO1203","volume":"36","author":"Culleton","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155377","article-title":"ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease","volume":"139","author":"Zhang","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.ekir.2026.106547_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105787","article-title":"Cellular cholesterol transport proteins in diabetic nephropathy","volume":"9","author":"Tsun","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.ekir.2026.106547_bib107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4239\/wjd.v12.i5.524","article-title":"New insights into renal lipid dysmetabolism in diabetic kidney disease","volume":"12","author":"Mitrofanova","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1016\/j.ekir.2026.106547_bib108","doi-asserted-by":"crossref","first-page":"26487","DOI":"10.1074\/jbc.M116.730564","article-title":"Exendin-4 ameliorates lipotoxicity-induced glomerular endothelial cell injury by improving ABC transporter A1-mediated cholesterol efflux in diabetic apoE knockout mice","volume":"291","author":"Yin","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ekir.2026.106547_bib109","doi-asserted-by":"crossref","DOI":"10.1177\/20543581231209012","article-title":"Precision medicine in diabetic kidney disease: a narrative review framed by lived experience","volume":"10","author":"Downie","year":"2023","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.ekir.2026.106547_bib110","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2337\/dc20-2839","article-title":"Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study","volume":"44","author":"Krist\u00f3fi","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib111","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106547_bib112","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106547_bib113","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib114","article-title":"Modeling cardiovascular protection with SGLT inhibition in type 1 diabetes: a risk-based approach to guide therapy?","volume":"48","author":"Kugathasan","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2215\/CJN.0000000641","article-title":"Modelling cardiorenal protection with SGLT2 inhibition in type 1 diabetes\u2013an analysis of DEPICT-1 and DEPICT-2","volume":"20","author":"Nardone","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib116","article-title":"Efficacy and safety of sotagliflozin in patients with type 1 diabetes and CKD","volume":"36","author":"Sridhar","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-025-01726-7","article-title":"Combining SGLT2is, GLP1-RAs and nsMRAs in diabetes: a scoping review of current and future perspectives","volume":"16","author":"Stougaard","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ekir.2026.106547_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-025-03723-6","article-title":"Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial","volume":"31","author":"Mahmud","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2026.106547_bib119","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Research Support, Non-U.S. Gov\u2019t review","volume":"24","author":"Skrtic","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2026.106547_bib120","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.eprac.2025.12.019","article-title":"Adolescents with type 1 diabetes using dapagliflozin as an adjunct-to-insulin: perspectives on experiences of clinical trial participation","volume":"32","author":"Anthony","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ekir.2026.106547_bib121","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"van Raalte","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib122","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"Van Der Velde","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106547_bib123","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ndt\/gfaf183","article-title":"Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations","volume":"41","author":"Heerspink","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106547_bib124","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2026.106547_bib125","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","article-title":"People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action","volume":"11","author":"Heerspink","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2026.106547_bib126","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types","volume":"2","author":"Tummalapalli","year":"2021","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.ekir.2026.106547_bib127","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.hlc.2025.05.095","article-title":"Implementation barriers to evidence-based cardiovascular-kidney-metabolic syndrome management","volume":"34","author":"Davis","year":"2025","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.ekir.2026.106547_bib128","doi-asserted-by":"crossref","DOI":"10.1177\/20543581231217857","article-title":"Identifying barriers and facilitators for increasing uptake of sodium-glucose cotransporter-2 (SGLT2) inhibitors in British Columbia, Canada, using the consolidated framework for implementation research","volume":"11","author":"Yi","year":"2024","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.ekir.2026.106547_bib129","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1002\/edm2.360","article-title":"Potassium management with finerenone: practical aspects","volume":"5","author":"Wanner","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.ekir.2026.106547_bib130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ekir.2023.12.012","article-title":"Barriers to care: new medications and CKD","volume":"9","author":"Kim","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106547_bib131","first-page":"158","article-title":"GLP-1 access and affordability: policy options and Market Strategies","volume":"6","author":"Emond","year":"2025","journal-title":"NEJM Catal Innov Care Deliv"},{"key":"10.1016\/j.ekir.2026.106547_bib132","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US","volume":"14","author":"Pearson","year":"2025","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ekir.2026.106547_bib133","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/diabetology6060052","article-title":"Addressing the shortage of GLP-1 RA and dual GIP\/GLP-1 RA-based therapies\u2014a systematic review","volume":"6","author":"Altabas","year":"2025","journal-title":"Diabetology"},{"key":"10.1016\/j.ekir.2026.106547_bib134","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/cd23-0023","article-title":"Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages","volume":"41","author":"Whitley","year":"2023","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ekir.2026.106547_bib135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.55222","article-title":"Factors associated with semaglutide initiation among adults with obesity","volume":"8","author":"Podolsky","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2026.106547_bib136","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03790322","article-title":"Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD","volume":"17","author":"McEwan","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib137","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ekir.2020.11.039","article-title":"Adherence to the kidney disease: improving global outcomes CKD guideline in nephrology practice across countries","volume":"6","author":"Stengel","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106547_bib138","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2468-2667(17)30141-X","article-title":"Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data","volume":"2","author":"Attaei","year":"2017","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ekir.2026.106547_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0004268","article-title":"Global availability of medications and health technologies for kidney care: a multinational study from the ISN-GKHA","volume":"5","author":"Kelly","year":"2025","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.ekir.2026.106547_bib140","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1111\/dom.15691","article-title":"Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: proof-of-concept results from the DECIDE-CV clinical programme","volume":"26","author":"Marques","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2026.106547_bib141","article-title":"Guideline-directed medical therapy for diabetic kidney disease: advances in primary and secondary prevention","volume":"18","author":"Verma","year":"2026","journal-title":"Cureus"},{"key":"10.1016\/j.ekir.2026.106547_bib142","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12882-020-01792-y","article-title":"Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes","volume":"21","author":"Nichols","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106547_bib143","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ajh\/hpae056","article-title":"Mind the gap in kidney care: translating what we know into what we do","volume":"37","author":"Luyckx","year":"2024","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ekir.2026.106547_bib144","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2213-8587(21)00240-0","article-title":"Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis","volume":"9","year":"2021","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:00:29Z","timestamp":1784577629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926027798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":144,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2468024926027798"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106547","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106547"}}